Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duvakitug - Teva Pharmaceuticals

Next Previous
Drug Profile

Duvakitug - Teva Pharmaceuticals

Alternative Names: SAR-447189; TEV-48574; TEV’574

Latest Information Update: 19 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Developer Sanofi; Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease; Ulcerative colitis
  • Phase II Asthma

Most Recent Events

  • 17 Feb 2026 Adverse events and efficacy data from the phase-IIb RELIEVE UCCD LTE trial in Ulcerative colitis and Crohn's disease released by Teva Pharmaceutical
  • 08 Oct 2025 Phase-III clinical trials in Ulcerative colitis (In adults, In adolescents, In the elderly, Treatment-experienced) in USA, Canada, Serbia, Puerto Rico, Japan (SC) (NCT07184996)
  • 02 Oct 2025 Sanofi initiates enrolment in the phase-III STARSCAPE-2 trial in Crohn's disease (In adults, In adolescents, In the elderly, Treatment-experienced) in USA (SC) (NCT07184944)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top